Clinical features of four patients with non-Hodgkin's lymphoma occurring during the course of inflammatory bowel disease
| No | Sex | Age at onset of IBD (y) | Age at onset of NHL (y) | Interval between IBD-NHL (y) | Interval between Tx-NHL (months) | Type of IBD | Site of IBD | Medical therapy of IBD | Type of NHL | Site/stage of NHL | Therapy for NHL | Outcome |
| 1 | M | 46 | 48 | 2 | 17 | UC | Extensive | Salazopyrine, prednisone, methotrexate 1/90–5/90 0.27 g, cyclosporin 5/90–5/91 27 4 g | Large cell diffuse B cell lymphoma | Mesenteric lymph nodes stage 1A | Surgical excision | Alive |
| 2 | M | 57 | 61 | 4.5 | 41 | UC (PSC) | Extensive | Salazopyrine, prednisone, methotrexate 12/90–5/94 2.73 g | Large pleiomorphic B cell lymphoma | Caecal with rectosigmoid involvement stage IVA | Surgical excision | Died from postop. sepsis |
| 3 | M | 48 | 53 | 4 | 14 | UC | Proctosigmoid | Salazopyrine, prednisone, azathioprine 4/94–5/95 57 g | Multifocal high grade B cell lymphoma | Rectum stage IVA | Surgical excision+ chemotx | In remission for 3 y |
| 4 | F | 32 | 34 | 2 | 9 | CD | Terminal ileum | Pentasa, prednisone, azathioprine 7/97–4/98 33.7 g | Large cell diffuse B cell lymphoma | Ileocaecal stage III | Surgical excision+ chemotx | Mediastinal recurrence May 1999 |
NHL, non-Hodgkins lymphoma; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn's disease; PSC, primary sclerosing cholangitis; chemotx, chemotherapy.